SCHEMBL981325

SCHEMBL981325

O=C(C=Cc1ccc(OCc2ccccc2)cc1)c1ccc(Cl)cc1

nearest known ligand 0.81

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 2/20 0.81
MAOB P27338 7/20 0.77
GSK3B P49841 2/20 0.65
BACE1 P56817 2/20 0.65
CYP1B1 Q16678 1/20 0.65
SLC5A1 P13866 1/20 0.62
SLC5A2 P31639 1/20 0.62
MAOA P21397 2/20 0.61
MAPT P10636 2/20 0.61
KMT2A Q03164 2/20 0.61
KDM4E B2RXH2 1/20 0.61
MEN1 O00255 1/20 0.61
TP53 P04637 1/20 0.61
PTGS1 P23219 1/20 0.60
PTGS2 P35354 1/20 0.60
NPC1 O15118 1/20 0.60
RAB9A P51151 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL981324 1.00 ABCG2 (0.81) ABCG2MAOBGSK3BBACE1CYP1B1
SCHEMBL16242554 0.91 ABCG2 (0.87) ABCG2MAOBGSK3BBACE1SLC5A1
SCHEMBL16242555 0.91 ABCG2 (0.87) ABCG2MAOBGSK3BBACE1SLC5A1
SCHEMBL25199731 0.90 ABCG2 (1.00) ABCG2MAOBGSK3BBACE1CYP1B1
SCHEMBL25223265 0.90 ABCG2 (1.00) ABCG2MAOBGSK3BBACE1CYP1B1
SCHEMBL25198204 0.87 ABCG2 (0.81) ABCG2MAOBGSK3BBACE1SLC5A1
SCHEMBL976816 0.87 MAOB (0.81) ABCG2MAOBGSK3BBACE1CYP1B1
SCHEMBL976815 0.87 MAOB (0.81) ABCG2MAOBGSK3BBACE1CYP1B1
SCHEMBL2647326 0.84 MAOB (0.76) ABCG2MAOBGSK3BBACE1SLC5A1
SCHEMBL2647325 0.84 MAOB (0.76) ABCG2MAOBGSK3BBACE1SLC5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872029-B2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states BOWEN J PHILLIP 2011-01-18 US disclosed
US-20090018167-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states Robinson, Thomas Philip (US) 2009-01-15 US disclosed
US-7432303-B2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states Bowen, J. Phillip (US) 2008-10-07 US disclosed
US-20050148599-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2005-07-07 US disclosed
US-6906105-B2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states BOWEN J PHILLIP (US) 2005-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018167-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states FLT1, FLT4, VEGFA ABCG2 659/4885MAOB 2526/4885GSK3B 408/4885
US-20050148599-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states FLT1, VEGFA, FLT4 ABCG2 535/4885MAOB 1509/4885GSK3B 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.